Key result
Single antiplatelet therapy after left atrial appendage closure was associated with a lower risk of hemorrhagic events without increasing embolic events.
Why the study?
The optimal post-procedural antithrombotic regimen following percutaneous left atrial appendage closure remains controversial.
Does single antiplatelet therapy reduce hemorrhagic events without increasing embolic events compared to other antithrombotic regimens in patients after left atrial appendage closure?
Cohort (n=140)
No
Does single antiplatelet therapy reduce hemorrhagic events without increasing embolic events compared to other antithrombotic regimens in patients after left atrial appendage closure?
Single antiplatelet therapy after LAA closure appears to offer a safer bleeding profile without compromising embolic protection compared to more intensive antithrombotic regimens.
Answers are grounded in this paper and cite their sources.
May favor SAPT post-LAA closure to reduce bleeding without embolic trade-off; leaves open randomized confirmation before practice change.
Background Percutaneous left atrial appendage (LAA) closure is a well-established strategy for stroke prevention in patients with non-valvular atrial fibrillation who have contraindications to long- term oral anticoagulation (OAC). However, the optimal post-procedural antithrombotic regimen remains controversial. Objective To review cardiovascular events including embolic and hemorrhagic events during the follow-up of patients who underwent LAA closure depending on the antithrombotic regimen. Methods We retrospectively analyzed 140 patients who underwent LAA closure at a single center between July 2016 and January 2025. The mean age was 76.4 years (range: 47.1–92.9). Indications for LAA closure included gastrointestinal bleeding (35%), recurrent ischemic stroke (25.71%), intracranial hemorrhage (21.43%), and other bleeding events (17.86%). Post-procedural antithrombotic regimens included dual antiplatelet therapy (DAPT) in 59 patients, single antiplatelet therapy (SAPT) in 37 patients, OAC in 19 patients, and combined OAC and antiplatelet therapy in 17 patients. Devices used were predominantly Amulet (120 patients), followed by Lambre (12 patients) and Watchman (3 patients). Mean follow-up was of 24.3 ± 14.7 months. Results The incidence of embolic events in the SAPT group was not higher compared to other regimens (χ² 25.34; p-value: 0.133). Hemorrhagic events were significantly lower in SAPT patients (χ²: 31.82; p value: 0.0015). Mortality rates increased over time: 7.86% at 1 year, 11.43% at 2 years, and 24.29% at 5 years. Conclusions Our findings highlight that patients on SAPT after LAA closure do not experience more embolic events compared to other antithrombotic strategies, while having a significantly lower risk of hemorrhagic events. These results emphasize the need for individualized post- procedural management to optimize safety and efficacy.
No takes yet. Share an insight, caveat, or question.
Alonso et al. (2025) conducted a cohort in Non-valvular atrial fibrillation with contraindications to long-term oral anticoagulation (n=140). Single antiplatelet therapy (SAPT) vs. Other antithrombotic regimens (DAPT, OAC, combined OAC and antiplatelet) was evaluated on Embolic and hemorrhagic events (p=0.133 for embolic events; 0.0015 for hemorrhagic events). Single antiplatelet therapy after left atrial appendage closure was associated with a lower risk of hemorrhagic events without increasing embolic events.
Synapse has enriched 10 related papers. Consider them for comparative context: